Abstracts tagged "Ulcerative Colitis"

Abstract Number: 1093 • 2019 ACR/ARP Annual Meeting
The US Prevalence of Inflammatory Bowel Disease and Associated Axial Pain: Data from the National Health & Nutrition Examination Survey (NHANES)
Oleg Stens¹, Charles Dillon ², Frederick W. Miller ³ and Michael Weisman ⁴, ¹Harbor-UCLA Medical Center, Torrance, CA, ²National Institutes of Health, Bethesda, MD, ³NIEHS, NIH, Bethesda, MD, ⁴David Geffen School of Medicine at UCLA, Los Angeles, CA
Background/Purpose: Associations between ulcerative colitis (UC) and Crohn’s disease, known together as inflammatory bowel disease (IBD), with axial pain, inflammatory back pain (IBP) and spondyloarthritis…
Abstract Number: 367 • 2018 ACR/ARHP Annual Meeting
Incidence of Inflammatory Bowel Disease (IBD) Among Patients (Pts) with Other Chronic Inflammatory Diseases (CID) Treated with Interleukin-17a (IL-17a) or Phosphodiesterase 4 (PDE4) Inhibitors
Bruno Emond¹, Lorie A. Ellis², Soumya D Chakravarty³, Martin Ladouceur¹ and Patrick Lefebvre¹, ¹Analysis Group, Inc., Montréal, QC, Canada, ²Janssen Scientific Affairs, LLC, Horsham, PA, ³Janssen Scientific Affairs, LLC/Drexel University School of Medicine, Horsham/Phila, PA
Background/Purpose: IBD is often associated with other CID, such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and psoriasis (PsO). Newer biologic agents…
Abstract Number: 1866 • 2018 ACR/ARHP Annual Meeting
Incidence of Inflammatory Bowel Disease Among Patients Treated with Ixekizumab: An Update on Adjudicated Data from an Integrated Database of Patients with Psoriasis and Psoriatic Arthritis
Mark C. Genovese¹, Jean-Frederic Colombel², Amanda M. Gellett³, Wen Xu³ and Dana Hardin³, ¹Department of Medicine, Stanford University, Palo Alto, CA, ²Department of Gastroenterology, The Mount Sinai Hospital, New York, NY, ³Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Increased incidence of IBD, such as Crohn’s disease (CD) and ulcerative colitis (UC), has been observed in patients (pts) with PsA or plaque psoriasis…
Abstract Number: 962 • 2016 ACR/ARHP Annual Meeting
No Increased Risk of Inflammatory Bowel Disease Among Secukinumab-Treated Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis: Data from 14 Phase 2 and Phase 3 Clinical Studies
Atul A. Deodhar¹, Stefan Schreiber², Kunal Gandhi³, Todd Fox⁴, Corine Gaillez⁴ and Chetan Karyekar³, ¹Oregon Health & Science University, Portland, OR, ²Christian-Albrechts-Universität Kiel, Kiel, Germany, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab, a fully human anti–interleukin-17A monoclonal antibody, has been evaluated and approved for the treatment of moderate to severe psoriasis, active psoriatic arthritis (PsA)…
Abstract Number: 2142 • 2015 ACR/ARHP Annual Meeting
Comparison of Interferon-y Release Assay Versus Tuberculin Skin Test in the Golimumab UC and the Golimumab SC Rheumatology (RA, PsA, and AS) Clinical Study Programs
Elizabeth C. Hsia^1,2, Neil Schluger³, John J. Cush⁴, Eric L. Matteson⁵, Stephen Xu¹, William Sandborn⁶, Paul Rutgeerts⁷ and Colleen Marano¹, ¹Janssen Research & Development, LLC, Spring House, PA, ²University of Pennsylvania, Philadelphia, PA, ³Columbia U College of Physicians & Surgeons, New York, NY, ⁴Baylor Research Institute, Dallas, TX, ⁵Division of Rheumatology, Department of Internal Medicine and Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁶Inflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla, California, La Jolla, CA, ⁷University Hospital Gasthuisberg, Leuven, Belgium
Background/Purpose: Interferon-ƴ release assays (IGRAs) offer the possibility of an improved method to detect TB infections in pts with autoimmune disorders. Compare results of…
Abstract Number: 2209 • 2014 ACR/ARHP Annual Meeting
Novel Biomarkers of Extracellular Matrix Remodeling in Inflammatory Bowel Disease: Different Patterns of Gut Injury in UC and CD
Joachim Høg Mortensen¹, Line Elberg Godskesen², Michael Dam Jensen², Lone Gabriels Klinge², Jens Kjeldsen², Aleksander Krag², Morten Karsdal³ and Anne C. Bay-Jensen⁴, ¹Cartilage Biomarkers and Research, Nordic Bioscience, Købehavn, Denmark, ²Odense University Hospital, Odense, Denmark, ³Research & Development, Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, ⁴Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark
Background/Purpose: About 10 % of patients with IBD have symptoms that match both Crohn's disease (CD) and ulcerative colitis (UC), termed inflammatory bowel disease unclassified…
Abstract Number: 805 • 2014 ACR/ARHP Annual Meeting
Takayasu Arteritis and Ulcerative Colitis –High Concurrence Ratio and Genetic Overlap
Chikashi Terao¹, Takayoshi Matsumura², Hajime Yoshifuji³, Yohei Kirino⁴, Yasuhiro Maejima⁵, Yoshikazu Nakaoka⁶, Meiko Takahashi¹, Eisuke Amiya², Natsuko Tamura⁵, Toshiki Nakajima³, Tomoki Origuchi⁷, Tetsuya Horita⁸, Mitsuru Matsukura², Yuta Kochi², Akiyoshi Ogimoto⁹, Motohisa Yamamoto¹⁰, Hiroki Takahashi¹¹, Shingo Nakayamada¹², Kazuyoshi Saito¹², Yoko Wada¹³, Ichiei Narita¹³, Yasushi Kawaguchi¹⁴, Hisashi Yamanaka¹⁴, Koichiro Ohmura³, Tatsuya Atsumi⁸, Kazuo Tanemoto¹⁵, Tetsuro Miyata², Masataka Kuwana¹⁶, Issei Komuro², Yasuharu Tabara¹, Atsuhisa Ueda¹⁷, Mitsuaki Isobe¹⁸, Tsuneyo Mimori³ and Fumihiko Matsuda¹, ¹Kyoto University Graduate School of Medicine, Kyoto, Japan, ²Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ³Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁴Yokohama City University Graduate School of Medicine, Yokohama, Japan, ⁵Tokyo Medical and Dental University, Tokyo, Japan, ⁶Osaka University Graduate School of Medicine, Osaka, Japan, ⁷Department of Health Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁸Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ⁹Ehime University Graduate School of Medicine, Ehime, Japan, ¹⁰Sapporo Medical University School of Medicine, Sapporo, Japan, ¹¹First Department of Internal Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan, ¹²The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ¹³Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, ¹⁴Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ¹⁵Kawasaki Medical School, Kurashiki, Japan, ¹⁶Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ¹⁷Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ¹⁸Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo, Japan
Background/Purpose . Takayasu arteritis (TAK) is a systemic vasculitis affecting large arteries and large branches of the aorta. Ulcerative colitis (UC) is a prevalent autoimmune…
Abstract Number: 2002 • 2013 ACR/ARHP Annual Meeting
Prophylactic Duration and Serum Uric Acid Level Are Associated With Gout Flare During Urate Lowering Treatment
Hyo-Jin Choi¹, Chan Hee Lee², Sang Tae Choi³, Jung-Soo Song³, Hyoun-Ah Kim⁴, Chang-Hee Suh⁵, Hoyeon Joo⁶, Ki Chul Shin⁷ and Hanjoo Baek¹, ¹Rheumatology, Gachon University Gil Hospital, Incheon, South Korea, ²Div Rheum Dept of Intl Med, NHIC Ilsan Hospital, Goyang-si, South Korea, ³Rheumatology, Chung-Ang University College of Medicine, Seoul, South Korea, ⁴Department of Rheumatology, Ajou University School of Medicine, Suwon, South Korea, ⁵Department of Rheumatology, Ajou University Hospital, Suwon, South Korea, ⁶Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea, ⁷Rheumatology, Seoul National University College of Medicine, Seoul, South Korea
Background/Purpose: To evaluate the clinical factors on gout flare during urate lowering treatment Methods: We retrospectively examined data derived from 228 patients who had been treated…

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.